Literature DB >> 23529704

Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals.

Kai M Eggers1, Tibor Kempf, Lars Wallentin, Kai C Wollert, Lars Lind.   

Abstract

BACKGROUND: Growth differentiation factor 15 (GDF-15) is emerging as a powerful risk indicator in both cardiovascular disease patients and community-dwelling individuals. We investigated GDF-15 concentrations and their changes over 5 years in elderly individuals from the community, together with the underlying conditions and prognostic implications of these measurements.
METHODS: We analyzed GDF-15 concentrations using a sandwich immunoassay in participants from the PIVUS (Prospective Investigation of the Vasculature in Uppsala Seniors) study. Measurements were performed at both 70 (n = 1004) and 75 (n = 813) years of age. Median follow-up was 8.0 years.
RESULTS: Over time, GDF-15 concentrations increased by 11.0% (P < 0.001). These changes were related to male sex, hypertension, diabetes, heart failure, renal function, and concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP). Significant relationships also emerged between changes in GDF-15 and changes in concentrations of NT-proBNP and C-reactive protein (CRP) and renal function between ages 70 and 75. The R(2) value of the model including all covariates was 0.20. GDF-15 concentrations independently predicted all-cause mortality [hazard ratio 4.0 (95% CI 2.7-6.0)] with results obtained at ages 70 and 75 as updated covariates. Baseline GDF-15 concentrations improved prognostic discrimination and reclassification [C statistic 0.06 (P = 0.006); integrated discrimination improvement = 0.030 (P = 0.004); category-free net reclassification improvement = 0.281 (P = 0.006)]. The change in GDF-15 concentrations over time independently predicted even all-cause mortality occurring after age 75 [hazard ratio 3.6 (95% CI 2.2-6.0)].
CONCLUSIONS: GDF-15 concentrations and their changes over time are powerful predictors of mortality in elderly community-dwelling individuals. GDF-15 concentrations increase with aging, and these changes are explained only partially by cardiovascular risk factors, indicators of neurohumoral activation and inflammation, and renal function. Thus GDF-15 reflects both cardiovascular and other biological processes closely related to longevity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23529704     DOI: 10.1373/clinchem.2012.201210

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  36 in total

1.  Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study.

Authors:  Daniel Lindholm; Stefan K James; Katja Gabrysch; Robert F Storey; Anders Himmelmann; Christopher P Cannon; Kenneth W Mahaffey; Philippe Gabriel Steg; Claes Held; Agneta Siegbahn; Lars Wallentin
Journal:  JAMA Cardiol       Date:  2018-12-01       Impact factor: 14.676

2.  Longitudinal course of GDF15 levels before acute hospitalization and death in the general population.

Authors:  Juliette Tavenier; Ove Andersen; Jan O Nehlin; Janne Petersen
Journal:  Geroscience       Date:  2021-03-24       Impact factor: 7.713

3.  Cardiovascular disease related circulating biomarkers and cancer incidence and mortality: is there an association?

Authors:  Manol Jovani; Elizabeth E Liu; Samantha M Paniagua; Emily S Lau; Shawn X Li; Katherine S Takvorian; Bernard E Kreger; Greta Lee Splansky; Rudolf A de Boer; Amit D Joshi; Shih Jen Hwang; Chen Yao; Tianxiao Huan; Paul Courchesne; Martin G Larson; Daniel Levy; Andrew T Chan; Jennifer E Ho
Journal:  Cardiovasc Res       Date:  2022-07-27       Impact factor: 13.081

4.  Brief Report: Statin Effects on Myocardial Fibrosis Markers in People Living With HIV.

Authors:  Christopher deFilippi; Robert Christenson; Jessica Joyce; Elli A Park; Ashley Wu; Kathleen V Fitch; Sara E Looby; Michael T Lu; Udo Hoffmann; Steven K Grinspoon; Janet Lo
Journal:  J Acquir Immune Defic Syndr       Date:  2018-05-01       Impact factor: 3.731

5.  Metabolic syndrome and Growth Differentiation Factor 15 in older adults.

Authors:  Adrián Carballo-Casla; Esther García-Esquinas; Antonio Buño-Soto; Ellen A Struijk; Esther López-García; Fernando Rodríguez-Artalejo; Rosario Ortolá
Journal:  Geroscience       Date:  2021-05-07       Impact factor: 7.581

6.  Growth differentiation factor-15 for prediction of bleeding in cancer patients.

Authors:  Frits I Mulder; Floris T M Bosch; Marc Carrier; Ranjeeta Mallick; Saskia Middeldorp; Nick van Es; Pieter Willem Kamphuisen; Phill S Wells
Journal:  J Thromb Haemost       Date:  2021-11-02       Impact factor: 16.036

7.  Change in Cardiac Biomarkers and Risk of Incident Heart Failure and Atrial Fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.

Authors:  Nisha Bansal; Leila R Zelnick; Elsayed Z Soliman; Amanda Anderson; Robert Christenson; Christopher DeFilippi; Rajat Deo; Harold I Feldman; Jiang He; Bonnie Ky; John Kusek; James Lash; Stephen Seliger; Tariq Shafi; Myles Wolf; Alan S Go; Michael G Shlipak
Journal:  Am J Kidney Dis       Date:  2020-12-09       Impact factor: 11.072

8.  Circulating Growth Differentiation Factor 15 Levels Are Associated With Risk of Both Intracerebral and Subarachnoid Hemorrhage.

Authors:  Lu Song; Martin Söderholm; Edith H Svensson; Yan Borné; Gunnar Engström
Journal:  Front Neurol       Date:  2021-06-09       Impact factor: 4.003

9.  Plasma growth differentiation factor-15 in patients with "lone" atrial fibrillation.

Authors:  Na Li; Qian Feng; Fangfang Yu; Jian Zhou; Xueyuan Guo
Journal:  J Clin Lab Anal       Date:  2022-03-25       Impact factor: 3.124

10.  Change in growth differentiation factor 15, but not C-reactive protein, independently predicts major cardiac events in patients with non-ST elevation acute coronary syndrome.

Authors:  Alberto Dominguez-Rodriguez; Pedro Abreu-Gonzalez; Idaira F Hernandez-Baldomero; Pablo Avanzas; Francisco Bosa-Ojeda
Journal:  Mediators Inflamm       Date:  2014-04-15       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.